Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)

NCT06343311 is registered in ClinicalTrials.gov with Estrella Immunopharma, Inc. as lead sponsor.

NCT NCT06343311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06343311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
Lead sponsor
Estrella Immunopharma, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 1, 2024
Completion date
July 31, 2028
Enrollment
27 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin's lymphoma (nhl), cns lymphoma, high-grade b-cell lymphoma, hiv associated lymphoma, large b-cell lymphoma, lymphoma, lymphoma, non-hodgkin, lymphoma, non-hodgkin's, adult, lymphoma, non-hodgkins, lymphomas non-hodgkin's b-cell, non-hodgkin lymphoma, non-hodgkin's lymphoma, refractory b-cell non-hodgkin lymphoma, refractory non-hodgkin lymphoma, relapsed non-hodgkin lymphoma